Skip to content
PoliticalRepoPoliticalRepo

United States · Bill · HR

H.R. 1136 (115th)

FDA Deeming Authority Clarification Act of 2017

referredUnited States· United States Congress· EN

Introduced

16 February 2017

Last action

17 February 2017 · Referred

Status

Referred to the Subcommittee on Health.

Sponsors

Rep. Cole, Tom [R-OK-4], Rep. Bishop, Sanford D. [D-GA-2], Rep. Stivers, Steve [R-OH-15], Rep. Thornberry, Mac [R-TX-13], Sen. Mullin, Markwayne [R-OK], Rep. Huizenga, Bill [R-MI-4], Rep. Kinzinger, Adam [R-IL-16], Rep. Yoder, Kevin [R-KS-3], Rep. Rogers, Harold [R-KY-5], Rep. Collins, Chris [R-NY-27], Rep. Holding, George [R-NC-2], Rep. Womack, Steve [R-AR-3], Rep. Amodei, Mark E. [R-NV-2], Rep. Sensenbrenner, F. James, Jr. [R-WI-5], Rep. Westerman, Bruce [R-AR-4], Rep. Fleischmann, Charles J. "Chuck" [R-TN-3], Rep. Murphy, Tim [R-PA-18], Rep. Bishop, Mike [R-MI-8], Rep. Guthrie, Brett [R-KY-2], Rep. Brat, Dave [R-VA-7], Rep. Smith, Adrian [R-NE-3], Rep. Kelly, Mike [R-PA-16], Rep. Harris, Andy [R-MD-1], Rep. Clay, Wm. Lacy [D-MO-1], Rep. Rooney, Francis [R-FL-19], Carlos Curbelo, Rep. Long, Billy [R-MO-7], Rep. Hudson, Richard [R-NC-8], Rep. Moolenaar, John R. [R-MI-2], Rep. Valadao, David G. [R-CA-22], Rep. Graves, Tom [R-GA-14], Rep. Coffman, Mike [R-CO-6], Rep. Shimkus, John [R-IL-15], Rep. Bacon, Don [R-NE-2], Rep. Peterson, Collin C. [D-MN-7], Rep. Rutherford, John H. [R-FL-5], Rep. Costa, Jim [D-CA-21], Rep. Higgins, Clay [R-LA-3], Rep. Jones, Walter B., Jr. [R-NC-3], Rep. Griffith, H. Morgan [R-VA-9], Rep. Blum, Rod [R-IA-1], Rep. Cuellar, Henry [D-TX-28], Rep. Tipton, Scott R. [R-CO-3], Rep. Perry, Scott [R-PA-10], Rep. Pittenger, Robert [R-NC-9], Rep. Walberg, Tim [R-MI-5], Rep. Peters, Scott H. [D-CA-50], Rep. Sanford, Mark [R-SC-1]

Subjects

Healthcare

Source updated

11 August 2025

Healthcare

Official sourceDownload fileView documentsShare

Summary

FDA Deeming Authority Clarification Act of 2017 This bill amends the Federal Food, Drug, and Cosmetic Act (FFDCA) to: (1) revise premarket review and reporting requirements for products newly deemed by the Food and Drug Administration (FDA) to be tobacco products; and (2) grant the FDA the authority to regulate vapor products, which include products that produce vapor with nicotine (e.g., e-cigarettes) and nicotine intended to be used with such a product (e.g., nicotine cartridges). A product is not subject to premarket review by the FDA if it is marketed before it is deemed a tobacco product. The bill delays deadlines for reports to the FDA on products similar to a marketed product that are introduced to market less than 21 months after that type of product is deemed a tobacco product. The bill grants the FDA regulatory authority over vapor products that is in addition to the FDA's existing authority to regulate vapor products as tobacco products. Provisions of the FFDCA applicable to tobacco product components also apply to vapor product batteries. The FDA must establish standards for vapor product batteries. Vapor products first marketed not later than 24 months after enactment of this bill are not subject to premarket review or reporting requirements based on changes to the product's battery to conform to standards. Vapor products may not be advertised in publications, except publications with adult readership. Vapor products may be sold only face-to-face, through vending machines in facilities where only adults are permitted, or by mail order. Vapor products must be labeled with their nicotine content and specified phrases. Retailers of vapor products must register with the FDA.

This text is taken from the official record. PoliticalRepo does not editorialize.

Timeline

  1. 16 February 2017

    Introduced

    Referred to the House Committee on Energy and Commerce.

    Source: IntroReferral

  2. 16 February 2017

    Introduced

    Introduced in House

    Source: IntroReferral

  3. 16 February 2017

    Introduced

    Introduced in House

    Source: IntroReferral

  4. 17 February 2017

    Referred

    Referred to the Subcommittee on Health.

    Source: Committee

Votes

No vote records are attached yet.

Versions

Documents

3 official files

Introduced in House (text)

View fileDownload file

This file cannot be previewed here. Use View or Download.

Leesvertaling

Vertaal dit document naar jouw taal. PoliticalRepo bewaart geen aparte kopie per EU-taal.

Documentvertaling op verzoek met downloadbare PDF (logo + link naar de officiële bron). Het bronbestand blijft leidend.

  • Introduced in House (text)

    Introduced in House · EN · 16 February 2017

    ViewDownloadOpen at official source

  • Introduced in House (PDF)

    Introduced in House · EN · 16 February 2017

    ViewDownloadOpen at official source

    Leesvertaling

    Vertaal dit document naar jouw taal. PoliticalRepo bewaart geen aparte kopie per EU-taal.

    Documentvertaling op verzoek met downloadbare PDF (logo + link naar de officiële bron). Het bronbestand blijft leidend.

  • Introduced in House

    summary · EN · 16 February 2017

    Open at official source

    Leesvertaling

    Vertaal dit document naar jouw taal. PoliticalRepo bewaart geen aparte kopie per EU-taal.

    Documentvertaling op verzoek met downloadbare PDF (logo + link naar de officiële bron). Het bronbestand blijft leidend.

Sponsors

Showing 48 of 95 sponsors and actors.

Related records

No cross-record relationships stored yet.

Sources

PoliticalRepo is an index and interpretation layer, not the authoritative legal source.